A single apheresis to achieve a high number of peripheral blood CD34
؉ cells in a lithiumtreated patient with acute myeloid leukaemia
The administration of G-CSF either alone or following chemotherapy has been used to augment the number of circulating haematopoietic progenitor cells in peripheral blood. However, the optimal mobilisation regimens to achieve the necessary progenitor thresholds with only one or two aphereses remain to be defined. 1 It has been recently reported that lithium therapy, given to psychiatric patients, may augment the number of CD34 ϩ cells in peripheral blood. 2 We report a lithium-treated patient with acute myeloid leukaemia in whom a high number of peripheral blood CD34
ϩ cells was achieved following G-CSF therapy for the mobilisation of progenitor cells.
A 33-year-old woman with a previous medical history of lithium therapy for bipolar disorder since 1991, was diagnosed as acute myeloid leukaemia (AML-M5 according to the FAB classification) in February 1997. /kg, determined by methods previously described. 3 At the time of mobilisation, the dose of lithium carbonate was 1200 mg/day and the serum lithium concentration was 0.86 mmol/l. No side-effects of lithium therapy were observed while lithium carbonate was administered. Lithium can increase the leukocyte level by raising the production of G-CSF 4, 5 and may also augment the number of CD34 ϩ cells. 2 The latter aspect could be of clinical importance in this case, bearing in mind that this was a patient with acute myeloid leukaemia. Although amongst normal donors the median of CD34 ϩ cells collected is around 4-5 ϫ 10 6 /kg, 6 it has been previously reported that extensive prior chemotherapy and malignancies different from breast cancer may be unfavourable factors for mobilisation of CD34 ϩ cells. 7, 8 In our centre, the number of CD34 ϩ cells in patients with acute myeloid leukaemia mobilised with G-CSF alone is lower. Besides the case reported here, we have performed 17 leukapheresis procedures in 15 patients diagnosed with acute myeloid leukaemia. After the first apheresis, the mean and median percentage of CD34 ϩ cells were 0.18 Ϯ 0.03% and 0.16%, respectively with a range from 0.02% to 0.36%. In these patients, the median number of aphereses was 3 (range [2] [3] [4] [5] [6] 
